Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Thomas
01.23.25
Pillsbury advised First Ascent Biomedical, a pioneer in personalized cancer treatment, in securing a $6 million investment from Vidal Duart Enterprises, Inc., with an additional co-investment from Techstars.
Leveraging advanced technologies to personalize cancer treatment, First Ascent Biomedical’s platform has been shown to significantly outperform standard care, offering a new frontier in oncology.
According to a company press release, the funding will accelerate First Ascent Biomedical’s mission to transform medical oncology with highly individualized, prospective treatment planning technologies that improve patient survival.
Click here to learn more.
Corporate associate Matt O’Brien served as counsel to First Ascent Biomedical.